The Zepbound Shortage Is Over — Here's What to Expect if You've Been Using an Off-Brand Version
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...
healthday on MSN5h
FDA Approves Generic GLP-1 Medicine For Diabetes Treatment
The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...
Elon Musk says he prefers Lilly’s Mounjaro over Novo’s Ozempic
CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.
Hosted on MSN7h
Peptides for Weight Loss: 5 Effective Medications According to Experts
Experts recommend 5 peptide-based medications for weight loss, such as liraglutide and semaglutide. They require medical ...
24/7 Wall St16h
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...
Northwest Naturals raw pet food tied to bird flu in cat; recall issued
The recall, according to a news release published Wednesday, involves Northwest Naturals' Feline Turkey Recipe raw frozen pet ...
Health risks from wildfire smoke linger 3 years after Marshall Fire
In a new study, researchers examined the health effects people experienced when they returned to still-standing homes after ...
Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy?
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
2025 Analyst Outlook: Edmund Ingham On Biotech Big And Small, And A Key Milestone
Lower interest rates boost biotech investments by increasing risk appetite, benefiting pre-commercial biotechs. Read more on how these companies may perform in 2025.